Company: BDRX
Filing Date: 2025-05-01
Form Type: DRS
Source: 0001214659-25-006756
Chunk: 53

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-01
Form: DRS
Chunk 53
---
 Deferred Shares of £0.001 nominal
value each.

On June 20, 2023, we issued
the Series C Warrants, Series D Warrants and May 2023 Placement Agent Warrants after receiving required shareholder approval of the allotment
of, and disapplication of pre-emption rights with respect to the Ordinary Shares to be issued under the warrants at our June GM.

Between June 20, 2023, and
December 31, 2024, we have issued 166,017,700 ordinary shares upon the exercise of Series C Warrants issued in the May 2023 registered
direct offering.

On July 5, 2023, we effected
a ratio change to the Depositary Shares, pursuant to which the ratio of ordinary shares to Depositary Shares was changed such that one
Depositary Share represented 400 ordinary shares. Our ordinary shares were not affected by this change and no fractional Depositary Shares
were issued.

On November 22, 2023, we entered
into a series of agreements with (1) Adhera Therapeutics, Inc. and certain of its secured noteholders, or the Secured Noteholders,
and (1) Melior. On December 21, 2023, in connection with the closing under the agreements, we issued (A) an aggregate of (i) 8,997 Depositary
Shares to certain of the Secured Noteholders and (ii) 90,999 pre-funded warrants to purchase Depositary Shares to certain of the Secured
Noteholders, or the December 2023 Private Placement Pre-Funded Warrants, and (B) 14,177 Depositary Shares to Melior. Between December
21, 2023 and April 1, 2025, we have issued 738,002,400 Ordinary Shares upon the exercise of December 2024 Private Placement Pre-Funded
Warrants issued to the Secured Noteholders.

On December 21, 2023, we completed
the closing of an underwritten public offering, pursuant to which we issued and sold (i) 43,555 Class A units, or Class A Units, at a
public offering price of $50.00 per Class A Unit, with each Class A Unit consisting of (a) one Depositary Share, (b) one Series E warrant,
or Series E Warrant, and (c) one Series F warrant, or Series F Warrant, and (ii) 76,